Robert Glassman Sells 10,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 10,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $29.82, for a total value of $298,200.00. Following the sale, the director owned 10,500 shares in the company, valued at $313,110. The trade was a 48.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Pharvaris Trading Up 1.7%

Shares of Pharvaris stock opened at $29.45 on Thursday. The business’s 50 day simple moving average is $28.32 and its 200-day simple moving average is $26.73. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of -9.26 and a beta of -2.34. Pharvaris N.V. has a twelve month low of $15.46 and a twelve month high of $33.33.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. Sell-side analysts predict that Pharvaris N.V. will post -3.25 earnings per share for the current year.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across multiple periods for Pharvaris, including FY2026 through FY2030, while reiterating a Buy rating and a $60 price target, signaling improved longer-term expectations for the clinical-stage biotech.
• Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, posting EPS of ($0.70) versus the consensus estimate of ($0.82), which supports sentiment but still reflects ongoing losses.
• Negative Sentiment: CEO Berndt Modig sold 2,292 shares at an average price of $29.22, trimming his position slightly and adding to investor focus on insider activity.
• Negative Sentiment: Director Robert Glassman sold 10,000 shares, and insider Wim Souverijns also sold 10,000 shares, which may weigh on sentiment because investors often view insider selling as a sign of reduced confidence. Robert Glassman SEC filing Wim Souverijns SEC filing

Wall Street Analyst Weigh In

PHVS has been the topic of a number of research reports. Wall Street Zen upgraded Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. UBS Group set a $74.00 price objective on Pharvaris in a report on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Royal Bank Of Canada decreased their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Finally, Wolfe Research initiated coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective for the company. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. General Atlantic L.P. grew its holdings in Pharvaris by 6.6% in the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares in the last quarter. Foresite Capital Management IV LLC grew its holdings in Pharvaris by 8.3% in the 3rd quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after buying an additional 368,000 shares in the last quarter. venBio Partners LLC boosted its stake in Pharvaris by 8.2% during the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after purchasing an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. boosted its stake in Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after purchasing an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP boosted its stake in Pharvaris by 26.5% during the 3rd quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after purchasing an additional 507,043 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.